Trial Outcomes & Findings for A Study of Two Different Formulations of LY3502970 in Healthy Participants (NCT NCT05341089)
NCT ID: NCT05341089
Last Updated: 2026-05-27
Results Overview
PK: Cmax of LY3502970 in Formulation 1 and Formulation 2
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
39 participants
Primary outcome timeframe
Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
Results posted on
2026-05-27
Participant Flow
Participant milestones
| Measure |
2 mg/4mg/8mg LY3502970 - Dose Titration Period
Participants received escalating oral doses of LY3502970 according to the following dosing schedule:
* Days 1-7: 2 milligrams (mg) once daily (QD)
* Days 8-14: 4 mg QD
* Days 15-21: 8 mg QD
|
16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period
Participants received 16 mg LY3502970 Formulation 1 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 2 orally QD from Days 29-35 in test period 2.
|
16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period
Participants received 16 mg LY3502970 Formulation 2 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 1 orally QD from Days 29-35 in test period 2.
|
|---|---|---|---|
|
Dose Titration Period
STARTED
|
39
|
0
|
0
|
|
Dose Titration Period
Received at Least One Dose of LY3502970
|
38
|
0
|
0
|
|
Dose Titration Period
COMPLETED
|
34
|
0
|
0
|
|
Dose Titration Period
NOT COMPLETED
|
5
|
0
|
0
|
|
Test Period 1
STARTED
|
0
|
17
|
17
|
|
Test Period 1
Received at Least One Dose of LY3502970
|
0
|
17
|
17
|
|
Test Period 1
COMPLETED
|
0
|
17
|
16
|
|
Test Period 1
NOT COMPLETED
|
0
|
0
|
1
|
|
Test Period 2
STARTED
|
0
|
17
|
16
|
|
Test Period 2
Received at Least One Dose of LY3502970
|
0
|
17
|
16
|
|
Test Period 2
COMPLETED
|
0
|
17
|
15
|
|
Test Period 2
NOT COMPLETED
|
0
|
0
|
1
|
Reasons for withdrawal
| Measure |
2 mg/4mg/8mg LY3502970 - Dose Titration Period
Participants received escalating oral doses of LY3502970 according to the following dosing schedule:
* Days 1-7: 2 milligrams (mg) once daily (QD)
* Days 8-14: 4 mg QD
* Days 15-21: 8 mg QD
|
16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period
Participants received 16 mg LY3502970 Formulation 1 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 2 orally QD from Days 29-35 in test period 2.
|
16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period
Participants received 16 mg LY3502970 Formulation 2 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 1 orally QD from Days 29-35 in test period 2.
|
|---|---|---|---|
|
Dose Titration Period
Adverse Event
|
4
|
0
|
0
|
|
Dose Titration Period
Physician Decision
|
1
|
0
|
0
|
|
Test Period 1
Adverse Event
|
0
|
0
|
1
|
|
Test Period 2
Withdrawal by Subject
|
0
|
0
|
1
|
Baseline Characteristics
A Study of Two Different Formulations of LY3502970 in Healthy Participants
Baseline characteristics by cohort
| Measure |
2 mg/4mg/8mg LY3502970 - Dose Titration Period
n=38 Participants
Participants received escalating oral doses of LY3502970 according to the following dosing schedule:
* Days 1-7: 2 milligrams (mg) once daily (QD)
* Days 8-14: 4 mg QD
* Days 15-21: 8 mg QD
|
|---|---|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=51 Participants
|
|
Region of Enrollment
Singapore
|
38 Participants
n=51 Participants
|
|
Age, Continuous
|
40.4 years
STANDARD_DEVIATION 10.5 • n=51 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=51 Participants
|
|
Sex: Female, Male
Male
|
34 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
38 Participants
n=51 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Asian
|
38 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
White
|
0 Participants
n=51 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=51 Participants
|
PRIMARY outcome
Timeframe: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdosePopulation: The pharmacokinetic population consisted of participants from the test period who received at least one dose of LY3502970 and had evaluable PK samples.
PK: Cmax of LY3502970 in Formulation 1 and Formulation 2
Outcome measures
| Measure |
16 mg LY3502970 (Formulation 1)
n=32 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 1) were included in this arm.
|
16 mg LY3502970 (Formulation 2)
n=33 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 2) were included in this arm.
|
|---|---|---|
|
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2
|
86.5 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 40
|
86.5 nanogram per milliliter (ng/mL)
Geometric Coefficient of Variation 43
|
PRIMARY outcome
Timeframe: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdosePopulation: The pharmacokinetic population consisted of participants from the test period who received at least one dose of LY3502970 and had evaluable PK samples.
PK:(AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
Outcome measures
| Measure |
16 mg LY3502970 (Formulation 1)
n=32 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 1) were included in this arm.
|
16 mg LY3502970 (Formulation 2)
n=33 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 2) were included in this arm.
|
|---|---|---|
|
PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
|
1260 Nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 38
|
1240 Nanogram*hour per milliliter (ng*h/mL)
Geometric Coefficient of Variation 40
|
PRIMARY outcome
Timeframe: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdosePopulation: The pharmacokinetic population consisted of participants from the test period who received at least one dose of LY3502970 and had evaluable PK samples.
PK: Tmax of LY3502970 in Formulation 1 and Formulation 2
Outcome measures
| Measure |
16 mg LY3502970 (Formulation 1)
n=32 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 1) were included in this arm.
|
16 mg LY3502970 (Formulation 2)
n=33 Participants
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 2) were included in this arm.
|
|---|---|---|
|
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2
|
6.00 Hours (h)
Interval 4.0 to 23.92
|
6.00 Hours (h)
Interval 2.0 to 12.0
|
Adverse Events
2 mg LY3502970 - Dose Titration Period
Serious events: 0 serious events
Other events: 23 other events
Deaths: 0 deaths
4 mg LY3502970 - Dose Titration Period
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
8 mg LY3502970 - Dose Titration Period
Serious events: 0 serious events
Other events: 17 other events
Deaths: 0 deaths
16 mg LY3502970 (Formulation 1)
Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths
16 mg LY3502970 (Formulation 2)
Serious events: 0 serious events
Other events: 24 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
2 mg LY3502970 - Dose Titration Period
n=38 participants at risk
Participants from the dose titration period who received 2 mg LY3502970 were included in this arm.
|
4 mg LY3502970 - Dose Titration Period
n=37 participants at risk
Participants from the dose titration period who received 4 mg LY3502970 were included in this arm.
|
8 mg LY3502970 - Dose Titration Period
n=34 participants at risk
Participants from the dose titration period who received 8 mg LY3502970 were included in this arm.
|
16 mg LY3502970 (Formulation 1)
n=33 participants at risk
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 1) were included in this arm.
|
16 mg LY3502970 (Formulation 2)
n=34 participants at risk
Participants from test periods 1 and 2 who received 16 mg LY3502970 (Formulation 2) were included in this arm.
|
|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal discomfort
|
2.6%
1/38 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/33 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.9%
2/34 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Gastrointestinal disorders
Abdominal distension
|
26.3%
10/38 • Number of events 13 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.4%
2/37 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
8.8%
3/34 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
3.0%
1/33 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.9%
1/34 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Gastrointestinal disorders
Constipation
|
5.3%
2/38 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.9%
1/34 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
6.1%
2/33 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Gastrointestinal disorders
Diarrhoea
|
5.3%
2/38 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.9%
2/34 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
9.1%
3/33 • Number of events 8 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.9%
2/34 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Gastrointestinal disorders
Nausea
|
23.7%
9/38 • Number of events 11 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
8.1%
3/37 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
17.6%
6/34 • Number of events 6 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
6.1%
2/33 • Number of events 4 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
14.7%
5/34 • Number of events 5 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Gastrointestinal disorders
Vomiting
|
34.2%
13/38 • Number of events 38 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
8.1%
3/37 • Number of events 8 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
17.6%
6/34 • Number of events 13 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
18.2%
6/33 • Number of events 13 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
11.8%
4/34 • Number of events 19 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Catheter site bruise
|
2.6%
1/38 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
27.3%
9/33 • Number of events 12 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
8.8%
3/34 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Catheter site erythema
|
7.9%
3/38 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
30.3%
10/33 • Number of events 10 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
29.4%
10/34 • Number of events 12 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Catheter site pain
|
0.00%
0/38 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.9%
1/34 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
12.1%
4/33 • Number of events 4 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
11.8%
4/34 • Number of events 5 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Catheter site phlebitis
|
0.00%
0/38 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/33 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
11.8%
4/34 • Number of events 4 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Catheter site swelling
|
0.00%
0/38 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
6.1%
2/33 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.9%
2/34 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
General disorders
Early satiety
|
5.3%
2/38 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/33 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Metabolism and nutrition disorders
Decreased appetite
|
34.2%
13/38 • Number of events 13 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.4%
2/37 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.9%
2/34 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/33 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
8.8%
3/34 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Nervous system disorders
Dizziness
|
7.9%
3/38 • Number of events 3 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
5.4%
2/37 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
6.1%
2/33 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.9%
1/34 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Nervous system disorders
Headache
|
7.9%
3/38 • Number of events 4 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.7%
1/37 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
17.6%
6/34 • Number of events 8 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
9.1%
3/33 • Number of events 4 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
14.7%
5/34 • Number of events 5 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
|
Nervous system disorders
Somnolence
|
0.00%
0/38 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/37 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
2.9%
1/34 • Number of events 1 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
6.1%
2/33 • Number of events 2 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
0.00%
0/34 • From baseline until end of follow-up (up to 49 days)
All participants who received at least one dose of LY3502970. Participants were analyzed based on the actual treatment they received.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: GT60